Overview
DNA Communications helps life sciences brands navigate the healthcare regulatory, scientific, and commercial landscape by delivering strategic, educational, and behavioral-change programs. It translates scientific information into memorable messages and builds campaigns and content using services like brand strategy, medical communications, corporate PR, events, media training, and market access consulting. The company differentiates itself through its networks (IPG DXTRA and The Weber Shandwick Collective) and an integrated approach that blends science translation with data-driven insights and audience-focused content. Its goal is to help clients communicate clearly, build reputation, and support better health outcomes across the product lifecycle.
Work here?Claim your company
Simplify's take
What believers are saying
- MM+M named DNA Small Healthcare Agency of the Year 2026, boosting recruiting power.
- Revenue jumped 43% to $26.5 million in 2024, showing strong client retention.
- Headcount rose from 64 to 87 by late 2024, and hiring continued in 2026.
What critics are saying
- NLRB cases 25-CA-344132 and 25-CA-348780 closed after 2026 settlements, signaling labor friction.
- Interpublic's Current Group structure can dilute DNA's autonomy as network priorities shift in 2027.
- Biotech clients cut communications spend quickly after missed data readouts, compressing DNA's pipeline.
What makes DNA Communications unique
- DNAHelix, launched November 2025, unifies biotech narratives from early science to commercialization.
- The Weber Shandwick Collective gives DNA global reach without sacrificing healthcare specialization.
- DNA won MM+M Agency of the Year Silver in 2025, validating creative and scientific execution.
Help us improve and share your feedback! Did you find this helpful?